Research Interests
The Faculty maintains an extensive database of individual research profiles. Structured around a fixed list of 70 broad research terms, profiles are maintained by staff themselves and are regularly updated. Be sure to make regular visits...
 | | |
|---|
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
| Dr Tzong-Tyng Hung
Prince of Wales Clinical SchoolStatement of Interests:
Secondary bone lesions (bone metastasis) is a major cause of mortality and morbidity in prostate cancer. The mechanisms of bone metastasis is still unclear. In order to study bone metastasis, we have developed murine models that are bone metastatic. Using various imaging and detection systems (microCT scans for small animals, Bioluminescence imaging, Fluorescent imaging and ultrasound) we are able to monitor development of bone metastatic lesions and pinpoint the site of bone tumours. Importantly, our models involve immune competent mice, which allows us to investigate the role of immune cells on the development of secondary bone tumours in prostate cancer and also evaluate potential therapies which include immunotherapies.
More...
| |
| Dr Aparajita Khatri
Prince of Wales Clinical SchoolStatement of Interests:
Cancer imaging and therapeutics; Specifically, targeted combination therapies involving novel combinations e.g gene therapy and traditional therapy (Collaborations with Prof david T curiel (Alabama,USA) & Dr. Leif Lindholm(Sweden). Biomedical applications of magnetic nanoparticles for cancer imaging and therapy (Collaboration with Dr Benjamin Thierry, South Australia)
More...
| |
| ![Show details for [<FONT SIZE=2 FACE="Verdana"><b>]Dr Carl A Power[</b><br>    <i>Prince of Wales Clinical Schoo](/icons/expand.gif) Dr Carl A Power
Prince of Wales Clinical SchoolStatement of Interests:
In the area of cancer biology in general and specifically prostate cancer biology. Research is focused on use of animal models to identify mechanisms of prostate cancer metastasis to bone, immune responses to prostate cancer and its bone metastases and preclinical assessment of treatments to prevent bone mets.
More...
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |
|
| |